Unknown

Dataset Information

0

Comparative efficacy of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) monotherapy versus combined EGFR-TKI and chemotherapy in resectable EGFR-mutant non-small cell lung cancer: a real-world multicenter retrospective study

ABSTRACT:

SUBMITTER: Fan M 

PROVIDER: S-EPMC12337044 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Combination of EGFR-TKI and Chemotherapy Versus EGFR-TKI Monotherapy as Neoadjuvant Treatment of Stage III-N2 EGFR-Mutant Non-Small Cell Lung Cancer.
| S-EPMC11224993 | biostudies-literature
Unknown Efficacy of EGFR-TKI Plus Chemotherapy or Monotherapy as First-Line Treatment for Advanced EGFR-Mutant Lung Adenocarcinoma Patients With Co-Mutations.
| S-EPMC8415777 | biostudies-literature
Unknown Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial.
| S-EPMC8517012 | biostudies-literature
Unknown Osimertinib as a neoadjuvant therapy in resectable EGFR-mutant non-small cell lung cancer: a real-world, multicenter retrospective study.
| S-EPMC11736587 | biostudies-literature
Unknown Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer.
| S-EPMC4367710 | biostudies-literature
Unknown The role of immunotherapy and chemotherapy combinations in TKI-resistant EGFR-mutant non-small cell lung cancer: insights from real-world evidence
| S-EPMC12344174 | biostudies-literature
Unknown Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma.
| S-EPMC9323840 | biostudies-literature
Unknown Elevating CDCA3 Levels Enhances Tyrosine Kinase Inhibitor Sensitivity in TKI-Resistant EGFR Mutant Non-Small-Cell Lung Cancer.
| S-EPMC8466783 | biostudies-literature
Unknown Semaphorin 7A promotes EGFR-TKI resistance in EGFR mutant lung adenocarcinoma cells.
| S-EPMC6338389 | biostudies-literature
Unknown Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) <i>versus</i> intercalated TKI with chemotherapy for <i>EGFR</i>-mutated nonsmall cell lung cancer.
| S-EPMC9574558 | biostudies-literature